Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium ...

Beren Therapeutics P.B.C.®, the parent company of Mandos LLC® and a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, today announced that data for adrabetadex, an ...

Patent covers pristine graphene–based biosensor technology to translate protease activity into measurable optical ...

New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual ...

The AI in precision medicine market shows strong growth prospects driven by the need for personalized therapies amid rising chronic diseases. Key opportunities include advancements in AI for ...

A team of researchers at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC has identified important differences in how early ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

BioVenic, a leading innovator in animal biotechnology and life sciences, is proud to announce the launch of its expanded suite of animal metabolomics solutions.

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.

Pilatus Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced the first patient ...

WHOOP, the human performance company, today announces that the first limited-edition collection drop of PROJECT TERRAIN, the multi-year collaboration between WHOOP and Samuel Ross ...